Rheumnow Podcast

Before You Know It (8.25.2023)

Dr. Jack Cush comments on the news and journal articles from the past week on RheumNow.com. This VEXAS scoring, scleroderma sine scleroderma and head scratchers from southeast Asia.

Mono- and Oligo- are Different (8.18.2023)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Pizza and Rheumatoid Arthritis (8.11.2023)

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology.

English for the Biologically-Challenged (8.4.2023)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Composite Measure to Inform Management of Bio-naïve Patients with Psoriatic Arthritis Sponsored by AbbVie Medical Affairs

Listen as rheumatologists Dr. Philip Mease and Dr. Saakshi Khattri share their insights on using composite measures to manage patients with psoriatic arthritis. In this podcast, they discuss four composite measures used in trials of an IL-23 inhibitor.

Pain in the Neck (7.28.2023)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  This week COVID persists, mortality stems from misdiagnosis, and cervical pain is more than a pain in the neck.

Ask Cush Anything Returns (7.21.2023)

Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"

Anti-Drug Antibodies with Biologics (7.13.2023)

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Scleroderma - Thick and Thin (6.30.2023)

Dr. Jack Cush Reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

What is Colchicine Worth (6.23.2023)

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?